Phase II Study of Fluconazole for Lymphocutaneous and Visceral Sporotrichosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00004938|
Recruitment Status : Completed
First Posted : February 25, 2000
Last Update Posted : June 9, 2006
I. Evaluate the efficacy of fluconazole in patients with lymphocutaneous or visceral sporotrichosis.
|Condition or disease||Intervention/treatment||Phase|
|Sporotrichosis||Drug: fluconazole||Phase 2|
Patients are treated with daily oral fluconazole for up to 24 months. Follow-up continues for at least 1 year.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||30 participants|
|Study Start Date :||August 1996|
|Study Completion Date :||August 1996|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004938
|Study Chair:||William Dismukes||University of Alabama at Birmingham|